Q-omics provides the consensus-scored COL14A1 profile across patient tissues and cancer cell-line models. COL14A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, COL14A1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, COL14A1 protein abundance shows 31,216 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight BLCA, and HNSC as cancer lineages where COL14A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL14A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL14A1 survival associations across molecular data types. COL14A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL14A1 RNA expression–survival associations across cancer types. High COL14A1 expression shows unfavorable associations in BLCA, KIRP, UVM and LGG, but favorable associations in ACC and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for COL14A1 RNA expression.
This table summarizes COL14A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for COL14A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL14A1 shows lower tumor expression in BLCA, KICH, COAD, KIRP, KIRC and THCA. The BLCA box plot shows higher COL14A1 RNA expression in normal versus tumor tissue (log2 FC = −3.405, t-test p < 0.001).
This table shows molecular features associated with COL14A1 in patient tissues and cancer cell lines. In patient samples, COL14A1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, COL14A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
